In Q4 2023, Cuu Long Pharmaceutical Joint Stock Company (in short: DCL) announced its consolidated financial report for the fourth quarter of the year. Amidst economic fluctuations, DCL implemented flexible strategies to maintain growth and aim for sustainable development.
By the end of Q4 2023, DCL achieved over 1.17 trillion VND in revenue, a 13% increase compared to 2022; total assets increased from 2.105 trillion VND to over 2.277 trillion VND; and equity rose from over 1.392 trillion VND to more than 1.451 trillion VND. This performance reflects the efforts of DCL’s leadership and all employees in the context of a still gloomy economy in 2023.
To achieve these results, DCL invested in expanding production lines and building new factories to meet the increasingly high quality demands of the market. The company continues to focus on producing and trading key products such as empty capsules, cancer drugs, and medical supplies.
In the field of manufacturing and supplying various types of empty capsules, Cuu Long Pharmaceutical is expanding the Vicancap factory on schedule. Accordingly, DCL has completed the construction of the basic construction package and proceeded to purchase equipment: sihi pumps, uvac pumps, color matching machines, dissolution shaking machines, and viscosity measuring devices. It is expected that by Q1 2024, the company will complete the installation of the HVAC system, connect the main production line, and officially inaugurate it for use.
In the medical equipment sector, with the goal of enhancing production capacity to meet domestic demand and aim for international markets, DCL continues to ensure the construction progress of the Benovas Medical Equipment Manufacturing Factory. By the end of Q4 2023, DCL had completed 80% of the manufacturing workshop’s construction, 100% of the electric station walls, distribution cabinets, chillers, gas storage, guard house, vehicle house, perimeter walls, and continued with other auxiliary construction tasks.
Furthermore, DCL’s pharmaceutical warehouse has been 100% completed and put into use; the R&D building has also completed 90% of the construction volume. It is anticipated that by Q1 2024, all construction items of the project will be completed, accepted by state authorities, and officially put into operation.
2023 also marked a significant digital transformation for DCL, indicating an important step in the company’s digital journey. Digital transformation, with clear development strategies and orientations, has enhanced management operations, effective data use, supported the leadership in making important, accurate decisions, and laid a solid foundation for the company’s long-term strategic implementation.
Besides investing in research and production, ensuring the material and spiritual life of employees, DCL also focuses on creating community value. With a vision for sustainable development and promoting harmonious development between the company and society, DCL has actively participated in community activities such as donating gifts to flood-affected areas in Central Vietnam; donating an automatic Real-Time PCR testing system to Vinh Long City’s health center; sponsoring scientific and technical conferences of major hospitals to develop the national healthcare system, and more. Last year, DCL continuously created the best conditions for taking care of employees’ lives through internal activities celebrating major holidays like International Women’s Day, National Day, trade union festivals, International Workers’ Day, International Children’s Day, Mid-Autumn Festival, building homes of love, and donating to employees in difficult circumstances.
The company’s trade union, in collaboration with the Vinh Long Provincial Labour Confederation, handed over “Trade Union Houses” to union members in difficult circumstances.
With the relentless efforts of its leadership and all employees, DCL has proudly received many important awards over the past year, contributing to affirming DCL’s position such as: Top 10 prestigious brands in Asia; Top 10 best places to work in Vietnam; the Cefixim 200 product awarded Top 10 quality products.
With sustained growth, DCL is steadily advancing towards the vision of becoming the most highly regarded pharmaceutical company in Vietnam by patients, partners, and employees through innovative, accessible, and high-quality products and services.
